Drugs / EYE201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06664502 | Nov 2024 → Mar 2026 overdue | diabetic macular edema, occlusion of tributary of retinal vein, wet macular degeneration | EyeBiotech Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EYE201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06664502 ↗ |
| Route | Intravitreal | “intravitreal administration” NCT06664502 ↗ |